Generic injectables market exceeds $11.2 billion

The generic injectables market exceeds $11.2 billion and numerous high-value injectable products will face patent expiry in major markets over the next decade, according to a new report available on companiesandmarkets.com, titled Hospital Injectable Drugs: Future Prospects for Generics & Biosimilars

As companies seek new ways to gain a competitive edge in maturing generics markets, injectables have become increasingly desirable to the major players. Companies like Teva, Sandoz, Mylan, Hospira and Hikma have all increased their presence in the injectables sector through acquisitions in the last couple of years. And interest has not been limited to established generic companies, as pharmaceutical majors like Pfizer have also become attracted to the generic injectables market.

The global injectables market has value of around $120 billion. While the lion's share remains with the innovative industry for the time being, the generic injectables sector already exceeds $11.2 billion and numerous high-value injectable products will face patent expiry in major markets over the next decade.